BOSTON–(BUSINESS WIRE)–Oct 18, 2018–Verastem, Inc. (Nasdaq: VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to advance the adaptation and affection of action of blight patients, today appear the arrangement of Ironwood Pharmaceuticals, Inc.’s Chief Banking Officer Gina Consylman to its Board of Directors. Ms. Consylman, who will additionally serve as the Chair of the Board’s Audit Committee, replaces Louise Phanstiel who is abrogation the Board to accompany added able opportunities.
In addition, Hagop Youssoufian, MSc, MD is transitioning to serve as Verastem Oncology’s Head of Medical Action from his above-mentioned role as Head of Hematology and Oncology Development. Dr. Youssoufian will be demography over responsibilities from Diep Le, MD, PhD who is dispatch bottomward as Chief Medical Officer. Kirk Taylor, MD has additionally aing the Aggregation as Chief Vice President, Medical Diplomacy Action and Operations.
“We are captivated to accept Gina and Kirk accompany the Verastem Oncology aggregation as we access this new aeon of advance with our aboriginal bartering artefact launch,” said Robert Forrester, President and Chief Controlling Officer of Verastem Oncology. “Gina brings a different banking accuracy to the Board of Directors with added than 25 years of acquaintance in the fields of accumulated finance, accounting and tax administration for commercial-stage biologic companies, including organizations abyssal through aboriginal bartering artefact launches. Kirk is an able medical diplomacy controlling and above-mentioned practicing analyst with all-inclusive acquaintance arch all-around cross-functional teams and auspiciously bringing biologic candidates and articles to market. On account of the absolute Board and administration team, we aboveboard acceptable Gina and Kirk and attending advanced to their insights and contributions.”
Mr. Forrester added, “Over the accomplished several years, Hagop has played a cardinal role in the advance and success of Verastem Oncology and I accept no agnosticism he will abide carrying acknowledged after-effects with distinction. The Board and I ambition to accurate our acknowledgment to Louise and Diep for their outstanding contributions and service. They accept anniversary played important roles in architecture the Aggregation into what we accept will be a acknowledged bartering organization. We ambition both Louise and Diep all the absolute best in their approaching endeavors.”
“Verastem Oncology is entering an agitative new affiliate and I am accustomed to accompany the Board of Directors to advice the Aggregation assassinate on its cardinal and bartering accumulated goals,” said Ms. Consylman. “I accept the Aggregation is well-positioned for the aing date of change with a able-bodied commercialization plan to advice abode the cogent unmet charge for the patients and families adversity from hematological malignancies.”
Ms. Consylman currently serves as Chief Vice President and Chief Banking Officer of Ironwood Pharmaceuticals, Inc., a bartering biotech company, area she oversees the finance, planning, accounting, tax, treasury and allowance functions. Above-mentioned to aing Ironwood, Gina was Vice President, Accumulated Ambassador and Principal Accounting Officer of Analogic Corporation, a healthcare and aegis technology solutions company, area she led the company’s all-around accounting and treasury teams. Above-mentioned to Analogic, Gina captivated chief akin accounting and accumulated ambassador positions at Biogen Inc. and Varian Semiconductor Equipment Associates, Inc. (acquired by Applied Materials, Inc.). She began her career in accessible accounting at Ernst & Young LLP. Ms. Consylman holds a Bachelor of Science amount in accounting from Johnson & Wales University, a Master of Science amount in taxation from Bentley University, and is a Certified Accessible Accountant.
Dr. Taylor brings added than 21 years of biologic industry acquaintance and 12 years in analytic convenance to Verastem Oncology. He has led cross-functional teams as Chief Medical Officer and Chief Vice President, accoutrement abounding genitalia of the apple including the United States, Europe, Latin America, North America and Asia. Dr. Taylor has captivated controlling administration positions at Pfizer, Actelion, Biogen, Alzheon, Sanofi Genzyme, Prescient Medicine and Finch Therapeutics. Dr. Taylor specializes in backward appearance development and medical affairs. Dr. Taylor accustomed his B.A. from Harvard University and his M.D. from SUNY Downstate. He completed his internship at Roosevelt Hospital Columbia University, his address at the Albert Einstein College of Medicine, and a Post Doctorate at The University of California San Francisco, area he additionally served as a adroitness member.
About Verastem Oncology
Verastem Oncology (Nasdaq: VSTM) is a bartering biopharmaceutical aggregation committed to the development and commercialization of medicines to advance the lives of patients diagnosed with cancer. We are apprenticed by the strength, application and adventuresomeness of those aggressive blight – committed in our dness to bear new therapies that not alone accumulate blight at bay, but advance the lives of patients diagnosed with cancer. Because for us, it’s personal.
Our aboriginal FDA accustomed artefact is now accessible for the analysis of patients with assertive types of blah non-Hodgkin’s lymphoma (iNHL). Our action comprises artefact candidates that seek to amusement blight by modulating the bounded bump microenvironment. For added information, amuse appointment www.verastem.com.
Forward Looking Statements Notice
This columnist absolution includes advanced statements about Verastem Oncology’s strategy, approaching affairs and prospects, including statements apropos the development and action of Verastem Oncology’s advance artefact COPIKTRA. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and agnate expressions are advised to analyze advanced statements, although not all advanced statements accommodate these anecdotic words. Anniversary advanced account is accountable to risks and uncertainties that could account absolute after-effects to alter materially from those bidding or adumbrated in such statement. Applicable risks and uncertainties include, amid added things, uncertainties apropos the bartering success of COPIKTRA in the United States; uncertainties apropos physician and accommodating acceptance of COPIKTRA, including those accompanying to the assurance and adeptness of COPIKTRA; the uncertainties inherent in analysis and development of COPIKTRA, such as abrogating or abrupt after-effects of analytic trials; whether and back any applications for COPIKTRA may be filed with authoritative authorities in jurisdictions alfresco of the United States; whether and back authoritative authorities in any added jurisdictions may accept any such added applications that may be filed for COPIKTRA, which will depend on the appraisal by such authoritative authorities of the benefit-risk contour appropriate by the accumulation of the adeptness and assurance advice submitted and, if approved, whether COPIKTRA will be commercially acknowledged in such jurisdictions; Verastem Oncology’s adeptness to obtain, advance and accomplish apparent and added bookish acreage aegis for COPIKTRA and its added artefact candidates; the scope, timing, and aftereffect of any acknowledged proceedings; decisions by authoritative authorities apropos labeling and added affairs that could affect the availability or bartering abeyant of COPIKTRA; that authoritative authorities in the U.S. or added jurisdictions, if approved, could abjure approval; whether preclinical testing of Verastem Oncology’s artefact candidates and basic or acting abstracts from analytic trials will be predictive of the after-effects or success of advancing or after analytic trials; that the timing, ambit and amount of agreement for Verastem Oncology’s artefact candidates is uncertain; the accident that third affair payors (including government agencies) will not balance for COPIKTRA; that there may be aggressive developments affecting its artefact candidates; that abstracts may not be accessible back expected; that acceptance of analytic trials may booty best than expected; that COPIKTRA or Verastem Oncology’s added artefact candidates will account abrupt assurance events, acquaintance accomplishment or accumulation interruptions or failures, or aftereffect in annoying assurance profiles as compared to their levels of efficacy; that COPIKTRA will be abortive at alleviative patients with lymphoid malignancies; that Verastem Oncology will be clumsy to auspiciously admit or complete the analytic development and closing commercialization of its artefact candidates; that the development and commercialization of Verastem Oncology’s artefact candidates will booty best or amount added than planned; that Verastem Oncology may not accept acceptable banknote to armamentarium its advised operations; that Verastem Oncology or Infinity Pharmaceuticals, Inc. will abort to absolutely accomplish beneath the duvelisib authorization agreement; that Verastem Oncology may be clumsy to accomplish added draws beneath its debt ability or access able costs in the approaching through artefact licensing, co-promotional arrangements, accessible or clandestine equity, debt costs or otherwise; that Verastem Oncology will not accompany or abide authoritative filings for its artefact candidates, including for duvelisib in patients with CLL/SLL or FL in added jurisdictions; and that Verastem Oncology’s artefact candidates will not accept authoritative approval, become commercially acknowledged products, or aftereffect in new analysis options actuality offered to patients.
Other risks and uncertainties accommodate those articular beneath the branch “Risk Factors” in the Company’s Annual Report on Form 10-Q for the annual aeon concluded June 30, 2018 as filed with the Securities and Exchange Commission (SEC) on August 8, 2018, its Annual Report on Form 10-K for the year concluded December 31, 2017 as filed with the SEC on March 13, 2018 and in any consecutive filings with the SEC. The advanced statements independent in this columnist absolution reflect Verastem Oncology’s angle as of the date hereof, and the Aggregation does not accept and accurately disclaims any obligation to amend any advanced statements whether as a aftereffect of new information, approaching contest or otherwise, except as appropriate by law.
View antecedent adaptation on businesswire.com:https://www.businesswire.com/news/home/20181018005792/en/
CONTACT: Verastem Oncology:
Brian Sullivan, 1 781-469-1636
Senior Director, Accumulated Development
Adam Silverstein, 1 917-697-9313
Joseph Rayne, 1 617-340-6075
KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY ONCOLOGY PHARMACEUTICAL GENERAL HEALTH
SOURCE: Verastem, Inc.
Copyright Business Wire 2018.
PUB: 10/18/2018 04:05 PM/DISC: 10/18/2018 04:05 PM
Everything You Need To Know About Chapter 12 Forms California | Chapter 12 Forms California – chapter 13 forms california
| Delightful in order to the blog, in this particular time period I’m going to demonstrate with regards to chapter 13 forms california